NovaBay Pharmaceuticals, Inc.
NBYAMEXHealthcare
$1.47
$-0.48(-24.62%)
Market Cap$39136127
P/E Ratio—
52W High$99.75
52W Low$1.11
NovaBay Pharmaceuticals, Inc. (NBY) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · NBY · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.00B | $0.01B | $0.01B | $0.01B | $0.01B |
| Cost of Revenue | $0.00B | $0.00B | $0.00B | $0.01B | $0.00B |
| Gross Profit | ($0.00B) | $0.01B | $0.01B | $0.01B | $0.01B |
| Gross Margin %(computed) | — | 66.26% | 58.19% | 54.02% | 63.85% |
| Operating Expenses | |||||
| R&D Expenses | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| G&A Expenses | $0.01B | $0.01B | $0.01B | $0.01B | $0.01B |
| Total Operating Expenses | $0.01B | $0.01B | $0.01B | $0.02B | $0.02B |
| Operating Income | ($0.01B) | ($0.01B) | ($0.00B) | ($0.01B) | ($0.01B) |
| Operating Margin %(computed) | — | -59.70% | -39.23% | -100.09% | -86.85% |
| Interest Income | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Interest Expense | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Income Before Tax | ($0.03B) | ($0.01B) | ($0.01B) | ($0.01B) | ($0.01B) |
| Income Tax Expense | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Net Income | ($0.02B) | ($0.01B) | ($0.01B) | ($0.01B) | ($0.01B) |
| Net Margin %(computed) | — | -73.85% | -92.20% | -73.65% | -57.08% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-3.80 | $-0.51 | $-27.83 | $-70.72 | $-36.82 |
| Wtd Avg Shares | 0.01B | 0.02B | 0.00B | 0.00B | 0.00B |
| EBITDA | ($0.01B) | ($0.01B) | ($0.00B) | ($0.01B) | ($0.01B) |
| EBITDA Margin %(computed) | — | -60.58% | -39.17% | -49.97% | -85.68% |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · B
Explore more NovaBay Pharmaceuticals, Inc. data
About NovaBay Pharmaceuticals, Inc. (NBY) Income Statement
NovaBay Pharmaceuticals, Inc. (NBY) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, NBY reported revenue of $0.00B, gross profit of ($0.00B) (gross margin —), and net income of ($0.02B) — a net profit margin of —.
Frequently asked questions
NBY · 4 questionsNovaBay Pharmaceuticals, Inc. (NBY) reported revenue of $0.00B for 2025, down 100.0% year-over-year.
NBY revenueNBY salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08